{"slug":"vip-glp-1","verification":{"valid":true,"entries":4,"head":"8694a1d6af17d0b5f80e46737622d285de4a7a6094e5e0f727b4e4964b800108"},"count":4,"sources":[{"id":"s1","type":"pubmed","url":"https://www.jci.org/articles/view/17500","title":"Vasoactive intestinal peptide as a new drug for treatment of primary pulmonary hypertension","quote":"It decreased the mean pulmonary artery pressure in our eight study patients, increased cardiac output, and mixed venous oxygen saturation... The 6-minute walk distance increased by 113 m... after 12 weeks VIP treatment","summary":"Small human study (n=8) of inhaled VIP in pulmonary hypertension showing hemodynamic and functional improvements.","claim_ids":["c1"],"found_by":"grok/grok-4.3","extra":{},"accessed_at":"2026-06-29T22:30:59.929Z","link_status":"ok","quote_status":"unverified","prev":"genesis","hash":"5e802c851018124f372bf59736083527a3757acaa10e6fcc36c7c423fcf018f0"},{"id":"s2","type":"pubmed","url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC9531956/","title":"Therapeutic potential of vasoactive intestinal peptide and its receptors in diabetes","quote":"Several studies have demonstrated that the specific binding of VIP with VPAC2 receptors on β-cells can stimulate insulin secretion in a glucose-dependent manner","summary":"Review covering VIP receptor mechanisms in glucose regulation.","claim_ids":["c2"],"found_by":"grok/grok-4.3","extra":{},"accessed_at":"2026-06-29T22:30:59.929Z","link_status":"ok","quote_status":"verified","prev":"5e802c851018124f372bf59736083527a3757acaa10e6fcc36c7c423fcf018f0","hash":"5f8b096db5a591d1b7e1e4dd1934a0c59813f3718cb7d9fa87842a03aed8b6d9"},{"id":"s3","type":"pubmed","url":"https://www.mdpi.com/1422-0067/26/24/11797","title":"Contribution of Vasoactive Intestinal Peptide to the Inhibitory Effects of GLP-2","quote":"These results provide the first evidence that in isolated mouse ileal preparations VIP contributes to the inhibitory effects of GLP-2 on the neurally induced contractile responses.","summary":"Mouse ileum study linking VIP to GLP-2 motility effects.","claim_ids":["c3"],"found_by":"grok/grok-4.3","extra":{},"accessed_at":"2026-06-29T22:30:59.929Z","link_status":"http_403","quote_status":"unverified","prev":"5f8b096db5a591d1b7e1e4dd1934a0c59813f3718cb7d9fa87842a03aed8b6d9","hash":"1a67b6ab66133b256cfafa1882d707b2855c00cd8be2033be1849b9375894d88"},{"id":"s4","type":"other","url":"https://www.nejm.org/doi/full/10.1056/NEJMoa2032183","title":"STEP 1 trial semaglutide weight loss results","quote":"participants lost an average of nearly 15% of their body weight","summary":"Landmark human trial quantifying weight loss magnitude used for load-reduction logic.","claim_ids":["c4"],"found_by":"grok/grok-4.3","extra":{},"accessed_at":"2026-06-29T22:30:59.929Z","link_status":"http_403","quote_status":"unverified","prev":"1a67b6ab66133b256cfafa1882d707b2855c00cd8be2033be1849b9375894d88","hash":"8694a1d6af17d0b5f80e46737622d285de4a7a6094e5e0f727b4e4964b800108"}]}